Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019
Open Access
- 17 April 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (6), 1410-1412
- https://doi.org/10.1093/cid/ciaa453
Abstract
(See the Major Article by Chu et al on pages 1400–9.)Keywords
Funding Information
- National Institutes of Health
- Division of Cancer Epidemiology and Genetics, National Cancer Institute
This publication has 22 references indexed in Scilit:
- Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway EpitheliaPLoS Pathogens, 2013
- Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ CulturesJournal of Virology, 2013
- Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic PotentialmBio, 2013
- A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusNature Genetics, 2013
- Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytesJournal of Leukocyte Biology, 2012
- Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionHepatology, 2010
- Interferon-λ Contributes to Innate Immunity of Mice against Influenza A Virus but Not against Hepatotropic VirusesPLoS Pathogens, 2008
- Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaquesNature Medicine, 2004
- IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complexNature Immunology, 2002
- IL-28, IL-29 and their class II cytokine receptor IL-28RNature Immunology, 2002